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The tartrate-resistant acid phosphatase (TRAP) is
present inmultiple tissues, including kidney, liver, lung,
spleen, and bone. Recent study of (TRAP) gene expres-
sion has provided evidence for distinct promoters
within the (TRAP) gene, suggesting that the gene has
alternative, tissue-preferred mRNA transcripts. Exami-
nation of endogenous (TRAP) exon 1B and 1C mRNA
transcripts revealed tissue-preferred transcript abun-
dance with increased exon 1B transcripts detected in
liver and kidney and increased exon 1C transcripts de-
tected in bone and spleen. In this investigation, we have
made transgenic mice that express a marker gene
driven by two candidate promoters, designated BC and
C, within the (TRAP) gene. The BC and C promoters are
2.2 and 1.6 kb, respectively, measured from the transla-
tion initiation site. Evaluation of BC transgenic lines
demonstrated robust expression in multiple tissues. In
contrast, significant transgene expression was not de-
tected in C transgenic lines. Evaluation of transgene
mRNAs in BC transgenic lines revealed that virtually all
expression was in the form of B transcripts, suggesting
that the tissue-preferred pattern of endogenous (TRAP)
was not replicated in the BC transgenic line. Likewise,
osteoclastogenic cultures from BC, but not C, transgenic
bone marrow cells expressed the transgene following
receptor activator of NFB ligand/macrophage colony-
stimulating factor stimulation. In conclusion, when
compared with the 2.2-kb BC portion of the (TRAP) pro-
moter region, the 1.6-kb C portion does not account for
significant gene expression in vivo or in vitro; produc-
tion of the bone- and spleen-preferred (TRAP) C tran-
script must depend on regulatory elements outside of
the 2.2-kb promoter. As the majority of currently inves-
tigated transcription factors that influence transcrip-
tional regulation of osteoclast gene expression bind
within the 1.6-kb C portion of the (TRAP) promoter, it is
likely that transcription binding sites outside of the
2.2-kb region will have profound effects on regulation of
the gene in vivo and in vitro.
Tartrate-resistant acid phosphatase (TRAP)1 is highly ex-
pressed in multiple tissues, including kidney, liver, lung, pan-
creas, spleen, bone, and intestine (1, 2). TRAP activity in the
liver and kidney is predominantly in liver parenchymal cells
and glomerular mesangial cells, respectively. TRAP activity in
spleen, lung, and pancreas has been credited to mononuclear
phagocytes (2), and TRAP expression in bone is attributed to
osteoclasts and their precursor cells.
Several mammalian TRAP genes have been cloned, and the
intron-exon structure of the TRAP gene is highly conserved in
all species studied to date, including mouse, rat, pig, and hu-
man (3–7). Endogenous TRAP expression, based on detection of
TRAP mRNA, has been revealed in a variety of tissues, includ-
ing adult and neonatal bone, heart, brain, kidney, liver, lung,
and spleen. Among these tissues, TRAP mRNA is most abun-
dant in the liver, kidney, and bone (2, 8). Investigations using
transgenic mice have employed 2-kb TRAP promoters to ex-
press selected genes in a tissue-restricted fashion. Sites of
transgene expression have included bone, liver, pancreas,
spleen, lung, heart, brain, colon, brown fat, kidney, small in-
testine, and thymus (2, 9, 10).
Recent study of murine TRAP gene expression suggests that
there may be tissue-specific TRAP promoters (8); as a result, it
has been proposed that the TRAP gene has three alternative
5-untranslated regions that align with the first base of exon 2
(Fig. 1). These have been designated exons 1A, 1B, and 1C (8).
It has been proposed that the promoter for exon 1B is respon-
sible for basal level TRAP mRNA expression in macrophages
and osteoclasts and is the major promoter utilized in nonhe-
matopoietic cells. The exon 1C promoter is suspected to con-
tribute to regulation of TRAP expression beyond basal expres-
sion in hematopoietic cells, such as macrophages and
osteoclasts (8). The exon 1A promoter function is unknown, as
1A mRNA transcripts were detected in adult mouse bone but
not in vitro or in neonatal bone.
To improve understanding of transcriptional regulation of
TRAP gene expression, we generated transgenic mice with
distinct TRAP promoter regions fused to a reporter gene. Pro-
moter regions consisted of the 2.2- or the 1.6-kb (relative to
ATG) regions of the TRAP promoter region. The 2.2-kb region
contained exons 1B and 1C, and the 1.6-kb region contained
only exon 1C (Fig. 1). Transgenic lines derived from animals
with the 2.2-kb promoter (BC mice) demonstrated robust tis-
sue-restricted reporter gene expression, whereas transgenic
* This work was supported by National Institutes of Health Grants
CA90434 and AR47302, the Roby C. Thompson Endowment, and the
University of Minnesota Cancer Center transgenic mouse core facility.
The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
§ Both authors contributed equally to this work.
** To whom correspondence should be addressed: Dept. of Orthopedic
Surgery, 420 Delaware St. MMC 806, University of Minnesota, Minne-
apolis, MN 55455. Tel.: 612-626-9934; Fax: 612-624-0944; E-mail:
clohi001@umn.edu.
1 The abbreviations used are: TRAP, tartrate-resistant acid phospha-
tase; NGFR, human nerve growth factor receptor; CDy, yeast cytosine
deaminase; RANKL, receptor activator of NFB ligand; MCSF, macro-
phage colony-stimulating factor; 5FC, 5-fluorocytosine; TG, transgenic;
HPRT, hypoxanthine-guanine phosphoribosyltransferase.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 280, No. 6, Issue of February 11, pp. 4888–4893, 2005
© 2005 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org4888
 at UQ Library on October 25, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
lines derived from animals with the 1.6-kb promoter (C mice)
failed to express significant gene expression. These findings
provided novel insight into understanding transcriptional reg-
ulation of the TRAP gene by establishing that the 2.2-kb pro-
moter is essential for gene expression in vivo, by determining
that the 1.6-kb promoter region is not sufficient for gene ex-
pression in vivo, and by suggesting that expression of the bone-
and spleen-preferred TRAP C transcript must depend on reg-
ulatory elements outside of the 2.2-kb TRAP promoter.
MATERIALS AND METHODS
Generation and Identification of Transgenic Mice—Two transgene
constructs comprised of a portion of the murine TRAP promoter and a
fusion gene containing a marker gene and a therapeutic gene were used
to generate mice. A plasmid, LNGCDySN, containing the NGFRCDy
fusion gene was provided by Paul Orchard (11). The NGFRCDy fusion
gene contained the truncated human nerve growth factor receptor
(NGFR) gene and the yeast (y) gene encoding cytosine deaminase
(CDy). The fusion gene was amplified by polymerase chain reaction
(PCR), using a sense oligonucleotide, Koz-NGFR-5-HinDIII (AAGCT-
TCCACCATGGGGGCAGGTGCCA) and an antisense oligonucleotide,
CDy-3-HinDIII (AAGCTTCGATCACTCACCAATATCTTC) and cloned
into pTRAP vector. The construct was designated BC-NGFRCDy.
pTRAP contains one promoter fragment (1285 to 1 relative to ATG)
and one 3-poly(A) tail fragment (2866 to3385 relative to ATG) from
mouse TRAP gene in pBluescriptSK. The second transgene, designated
C-NGFRCDy, was generated by deletion of a 620-bp fragment (2160
to 1541 relative to ATG) from BC-NGFRCDy. The BC-NGFRCDy
and C-NGFRCDy transgenes were excised by removing pBluescriptSK,
purified with a QiAquick gel extraction kit (catalogue number 28706;
Qiagen Inc., Valencia, CA), and purified DNA was diluted to 4 ng/l in
a TE buffer (5 mM Tris, pH 7.5, 0.1 mM EDTA, pH 8.0).
Transgenic mice were produced by pronuclear microinjection of pu-
rified DNA into C3H/HeJ(F)  C57B1/6 (M) embryo eggs by the Uni-
versity of Minnesota Mouse Genetics Laboratory. Founder mice and
offspring were identified by Southern blot.
Real-time Quantitative RT-PCR—RNA was isolated and purified
using TRIzol (Invitrogen). Expression levels of mRNA were determined
using two-step qPCR, with SYBR green as a detection method. cDNA
templates for PCR amplification were prepared using a Retroscript™
first strand synthesis kit for RT-PCR (Ambion Inc., Austin, TX). Ran-
dom decamers were used to amplify 1.25 g of total RNA according to
the manufacturer’s instructions in a reaction volume of 20 l. 2 l of
this cDNA reaction volume were added to 23 l of a PCR master mix for
a final real-time quantitative reaction volume of 25 l. The PCR master
mix was prepared using Qiagen’s Quantitect™ SYBR® green PCR kit
(Qiagen). Four sets of primer pairs were used: NGFRCDy-F3, CAGAA-
CAAGACCTCATAGCC and NGFRCDy-R1, GACATCCGCCAATAG-
GAACA (NGFRCDy fusion gene); TRAP 1B-F, GCGCCGCCTCTTC-
CCAACTC and NGFRCDy-R4, CGGAGAACGTCACGCTGTCCA (exon
1B transgene transcript); TRAP 1C-F, ACTGCCTCTTGCAGCCTCTC
and NGFRCDy-R3, ACTCGGTGCACGGCTTGCAC (exon 1C trans-
gene transcript); and HPRT-F, GTAATGATCAGTCAACGGGGGAC
and HPRT-R, CCAGCAAGCTTGCAACCTTAACCA (HPRT). HPRT
was used for comparison and determination of relative ratio between
samples. All primers used had a final concentration of 0.3 M. Real-time
quantitative RT-PCR analysis was performed using the ABI PRISM
7900 sequence detection system instrument and software (PE Applied
Biosystems, Inc., Foster City, CA). Thermal cycling conditions were set
according to the manufacturer’s directions. Quantitated mRNA values
were normalized by the amounts of HPRT mRNA, and results are given
as -fold induction.
Western Analysis—Transgenic mouse tissue (at least 100 mg) was
homogenized in 0.5 ml of ice-cold lysis buffer (50 mM Tris-HCl, pH 7.6,
150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 0.1% SDS, 1 mM NaF, 1
mM Na3PO4) containing protease inhibitor mixture tablets (Roche Ap-
plied Science). The homogenate was allowed to settle on ice for 20 min
and then was centrifuged for 2 min at 14,000  g in a microcentrifuge
at 4 °C. Supernatant was decanted and stored at 80 °C. 700 g of cell
lysate/lane was separated on a 10% reducing SDS-PAGE and trans-
ferred to nitrocellulose membrane (Schleicher & Schuell). Polyclonal
anti-cytosine deaminase (catalogue number 2485-4906; BIOTREND,
Destin, FL) were applied at dilutions of 1:1000 and bovine anti-sheep-
horseradish peroxidase (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) at 1:3000.
Cell Culture—To determine whether transgenic (TG) bone marrow
expressed NGFR in vitro, replicate wells containing 4.5  104 TG or
C3H/HeJ bone marrow cells, 20 ng/ml receptor activator of NFB ligand
(RANKL) (Amgen Corp., Thousand Oaks, CA), and 30 ng/ml macro-
phage colony-stimulating factor (MCSF) (R&D Systems, Minneapolis,
MN) in 0.2 ml were cultured in 96-well plates. After 6 days, wells were
stained for TRAP (Sigma) or NGFR immunocytochemistry.
NGFR Immunocytochemistry—Monoclonal mouse anti-human
NGFR (clone 20.4, provided by Dr. Paul Orchard) was diluted 1:500 and
incubated at 37 °C for 1 h. A biotinylated goat anti-mouse IgG (Rock-
land) was used as the secondary antibody (1:750 dilution, 30 min at
37 °C), and the tertiary reagent was horseradish peroxidase avidin-
biotin complex (HRP-ABC; Vector Labs, Burlingame, CA).
In Vitro Cytotoxicity Assay—To assess the effect of 5-fluorocytosine
(5FC) on osteoclastogenesis, TG or C3H/HeJ bone marrow cells (4.5 
104/well), RANKL, and MCSF were cultured in 96-well plates with or
without various doses of 5FC (0.05–1.0 mM). TRAP solution assay was
performed on day 6 and enzyme activity read using an enzyme-linked
immunosorbent assay plate reader at 405 nm (12). Cytotoxicity was
determined by calculation of percent osteoclasts, as measured against
wells containing no drug.
Immunohistochemistry—Paraffin-embedded sections were cut at 6 m
and mounted onto SuperfrostPlus™ slides as described previously (13).
Statistics—Replicate wells were averaged for each drug dose, and
data are presented as mean  S.E. of three or four different animals.
Statistical significance was determined by Student’s t test. A p value
0.05 was considered statistically significant.
RESULTS
Generation of Transgenic Lines—medTransgenic lines con-
taining BC-NGFRCDy or C-NGFRCDy were generated by mi-
croinjection of either construct into fertilized C57BL/6  C3H/
FIG. 1. Schematic diagram of the
mouse TRAP gene and transgene
constructs. A, overview of the mouse
TRAP gene promoter (8), which consists
of three exons, and the translation initia-
tion site (A1TG) located at the beginning
of exon 2. The three TRAP mRNA tran-
scripts include exons 1A, 1B, or 1C. B,
transgene BC consists of TRAP gene 1B
and 1C promoter regions, an NGFRCDy
fusion gene replacing the coding region
for TRAP, and the 3-poly(A) tail. C,
transgene C is similar to BC except the
1B promoter region has been deleted.
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HeJ F1 mouse embryos. The presence of the transgene was
determined by Southern blot. Founder mice were mated with
C3H/HeJ mice, and the transgene in offspring was determined
by PCR. The four BC-NGFRCDy mouse lines containing the B
and C regions of the TRAP promoters were designated BC1–4,
and the three C-NGFRCDy mouse lines containing the C re-
gion of the TRAP promoter were designated C1–3.
Southern blot analysis probing for the NGFR portion of each
transgene demonstrated that the relative gene dosages in the
BC-NGFRCDy and C-NGFRCDy transgenic lines spanned
similar ranges. The estimated relative gene dosages for mice
with the 2.2-kb promoter (BC) ranged from 1.0 to 3.7, and the
estimated relative gene dosage for mice with the 1.6-kb pro-
moter (C) ranged from 1.3 to 4.4 (Fig. 2). Southern probe
targeting the B portion of the TRAP promoter detected endog-
enous TRAP gene in all lines, no gene in the C lines (as
expected), and transgene in each of the BC lines (Fig. 2). The
relative gene dose for BC lines based on Southern blots probed
for the B region was qualitatively similar to gene dose esti-
mates based on Southern blots probed for detection of NGFR.
Comparison of Transgene Expression in BC and C Trans-
genic Mice—Transgene expression was higher in BC mice than
in C mice. mRNA expression in kidney, liver, lung, spleen,
bone, brain, and heart was determined in seven lines of mice.
Quantitative real-time RT-PCR using primers for total
NGFRCDy mRNA revealed easily quantifiable expression of
the transgene in each tissue examined from BC transgenic
mice. Highest transgene expression was noted in liver and
kidney (Fig. 3). Significant expression was seen in the lung,
spleen, and bone. Minimal expression was present in the heart
and brain. In contrast, transgene expression in C transgenic
mice was not detectable in liver, kidney, spleen, lung, bone, and
heart and was minimally detectable in brain. Evaluation of
endogenous TRAP mRNA transcript expression in the trans-
genic mice revealed expected findings and confirmed a previous
report describing transcript distribution (8).
Total Transgene Transcript Expression in BC Mice—A gen-
eral pattern of gene expression was noted in each of the four BC
transgenic lines. Highest expression was detected in kidney
and liver; lower expression was noted in lung, bone, and spleen
(Fig. 3). Specifically, in three of the four BC lines, transgene
expression was greatest in the kidney. In one line, expression
was greatest in the liver. In all four BC lines, expression in the
liver and kidney ranged from 10 to several hundred times
greater than expression in lung, spleen, or bone.
Exon 1B and Exon 1C Transcript Expression in BC Mice—To
determine relative transcript expression in the BC transgenic
mice, quantitative real time PCR for the exon 1B or 1C tran-
scripts was performed. Findings indicate that the exon 1B
transcripts were the dominant transcript in each BC line.
Measurements of exon 1B transcript expression in each of the
four BC lines provided data mirroring findings from detection
of the NGFR transcript (Fig. 4, A and B). Between mice in each
FIG. 2. Southern blot analysis of BC and C transgenes in trans-
genic lines. A, analysis of four BC and three C lines using a probe
specific for the NGFRCDy fusion gene. This probe results in a 3.9-kb
band in BC mice and a 3.5-kb band in C lines. The relative transgene
dosage (TG dose) was estimated by comparing band intensity, with BC4
referenced as 1. B, analysis of mouse lines using a probe specific for the
1B region of the TRAP promoter. As expected, only BC lines show the
3.9-kb band of the transgene, and all transgenic lines show a faint band
representing endogenous TRAP gene (TRAP).
FIG. 3. Comparison of total mRNA expression for the trans-
gene in BC transgenic lines. mRNA expression using primer pairs
for the NGFRCDy fusion gene shows high expression in liver and
kidney (A) and lower (note scales) expression in bone, spleen, and lung
(B) in all four BC lines. Ratios are relative to HPRT.
FIG. 4. Comparison of exon 1B and 1C transgene transcripts in
BC transgenic lines. Quantitation of mRNA using primers specific for
exon 1B transgene transcript (A and B) or exon 1C transgene transcript
(C) in different tissues. Note differences in relative ratio scales. Ratios
are relative to HPRT.
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BC line, kidney and liver had the highest levels of expression.
Expression levels ranged from 10- to several hundred-fold
higher than spleen, lung, or bone in each animal. Evaluation of
exon 1C transcript levels revealed minimal expression in all
tissues and did not show evidence of tissue-specific transcript
expression (Fig. 4C).
Detection of NGFRCDy Fusion Protein in Transgenic Mice—
Western blot analysis of CDy protein demonstrated protein in
the liver, kidney, and bone of BC mice (Fig. 5A). Western blot
analysis did not detect protein in any tissue from C mice (data
not shown). The NGFRCDy fusion protein is commonly de-
tected as two bands (13). Interestingly, kidney and bone dis-
played a single 63-kDa band, compared with liver which dis-
played 67 and 63-kDa bands, suggesting that there is tissue-
specific post-translational modification of the NGFRCDy
fusion protein. Immunohistochemical detection of NGFR local-
ized protein to the cell membrane of hepatocytes and renal
tubular cells (Fig. 5, B–E) in BC, but not in C, mice.
Evaluation of Transgene Expression in Vitro—Under oste-
oclastogenic conditions in vitro, cells from BC and C transgen-
ics had increased expression of the endogenous TRAP gene, but
only cells from BC mice exhibited increased expression of the
NGFRCD transgene. To induce osteoclast or macrophage dif-
ferentiation, bone marrow cells from BC or C mice were cul-
tured in the presence of MCSF and RANKL or MCSF alone,
respectively. Endogenous TRAP expression increased in oste-
oclastogenic, but not macrophage, cultures containing cells
from BC or C mice (Fig. 6A). In culture systems from BC mice,
transgene expression increased significantly upon exposure to
MCSF alone (Fig. 6B). Interestingly, in culture systems from C
mice, transgene induction was not observed under either oste-
oclastogenic or macrophage differentiation conditions (Fig. 6B).
To further characterize the effect of RANKL and MCSF treat-
ment on TRAP and transgene expression in vitro, detection of
the B and C transcripts was performed in normal and BC cells.
Findings revealed that the endogenous exon 1B and exon 1C
TRAP transcripts were induced following RANKL and MCSF
treatment (Fig. 6, C and D). Likewise, expression of the trans-
genic exon 1B and 1C transcripts was also induced under
osteoclastogenic conditions (Fig. 6, E and F).
Detection of Transgenic Fusion Protein in Vitro—Findings
from histochemical and immunohistochemical evaluation of
osteoclastogenic culture systems were consistent with data
from evaluation of gene expression. TRAP enzyme detection
demonstrated that osteoclasts formed in culture (Fig. 7, B and
D). Immunohistochemical detection of the NGFR portion of the
NGFRCDy fusion protein demonstrated the presence of the
fusion protein in osteoclastogenic culture systems derived from
BC mice but, as expected, not from C3H control mice (Fig. 7,
A and C).
Detection of the CDy portion of the NGFRCDy fusion protein
was performed using an assay based on cytosine deaminase
enzyme activity. As CDy converts metabolically inert 5-fluoro-
cytosine to the cytotoxic agent 5-fluorouracil, exposure of CDy-
expressing osteoclastogenic cell culture systems to 5FC should
result in a reduction in osteoclast number (13). Treatment of
osteoclastogenic culture systems from nontransgenic mice had
no effect on osteoclast number. In contrast, treatment of oste-
oclastogenic culture systems derived from BC mice with 5FC
resulted in reduction in the number of osteoclasts (Fig. 7E).
5FC doses as low as 0.05 mM eliminated 60% of the osteoclasts
in BC culture systems, and the maximal effect was seen with
doses at or above 0.1 mM 5FC.
DISCUSSION
The primary objective of this investigation was to compare
transgene expression in transgenic mice with a reporter gene
(NGFRCDy) regulated by either the 2.2- (BC) or the 1.6-kb (C)
portion of the TRAP promoter. Findings demonstrated that
transgene expression was robust in mice with the BC promoter
and that transgene expression was essentially absent in mice
with the C promoter. Immunohistochemistry of liver and kid-
ney detected NGFR in BC, but not C, mice. In vitro osteoclas-
togenic conditions stimulated significant transgene expression
in marrow cells from BC, but not C, mice and immunohisto-
chemical detection of NGFR-positive osteoclasts.
Our analysis of gene expression driven by the 2.2- and
1.6-kb regions of the TRAP promoter indicated robust expres-
sion from the BC promoter and nil expression from the C
promoter in vivo. This finding was unexpected, as a previous
analysis of TRAP mRNA from various mouse tissues provided
evidence that the C region of the TRAP promoter may be
sufficient for substantial gene expression (8). Low expression
of the transgene in our C mice could not be explained by
relative transgene copy dose, as estimates of transgene copy
dosage range were similar in the BC and C mice. The domi-
nant transgenic transcript in BC mice was the B transcript,
with C transcripts being barely detectable. This finding was
particularly interesting because analysis of endogenous
TRAP mRNA transcripts in the transgenic mice indicated
that endogenous C transcripts were abundant in bone and
spleen, as has previously been reported (8).
Based on previous determination of the relative abundance
of distinct TRAP mRNA transcripts and our current analysis of
endogenous TRAP transcript expression, we expected to ob-
serve that tissue- or cell type-specific transcripts would be
present in hemopoietic (bone, spleen) versus nonhematopoietic
(kidney, liver) tissues (8). In contrast, we determined that
transcripts derived from the 2.2-kb promoter region showed
near complete fidelity to exon 1B. Taken in total, our in vivo
finding of limited exon 1C transcript levels suggested that the
most 5-portion of the TRAP gene containing 6.5 to 2.2-kb
(relative to ATG) may be required for generation of the exon
1C transcript.
Several transcription factors involved in osteoclast formation
FIG. 5. Demonstration of NGFRCDy fusion protein in BC
line. A, Western analysis for CDy shows expression in liver, kidney,
lung, and bone from BC (lanes 3, 5, 7) mice, but not control C3H.
NGFRCDy-expressing cell line is shown as a positive control for Cdy,
and -tubulin is used as the loading control. Immunohistochemical
staining (brown) for NGFR in kidney (B, D) and liver (C, E) from BC
(B, C) or C mouse (D, E). No staining is present in C mice. Kidney
1000 and liver 400 magnification.
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and activity have been shown to interact with the TRAP pro-
moter. These include MITF, Pip, PU.1, USF1, USF2, TFE3,
and TFEC (14–18). Each of these DNA binding proteins has
been studied in in vitro TRAP promoter-reporter experimental
systems, and transcription factor binding sites have been local-
ized to the 3-end of the TRAP promoter within the C region. As
our findings demonstrated that the C region of the TRAP
promoter alone is not sufficient for transgene expression, fur-
ther investigation is warranted to decipher the transcription
factor binding sites within the B region that permit vigorous
TRAP gene expression in vivo.
It is becoming increasingly clear that a complex set of regu-
latory mechanisms controls TRAP gene expression and tran-
scriptional events in TRAP-expressing cells (8). This work has
improved our understanding of TRAP gene regulation in oste-
oclasts by demonstrating that the 1.6-kb promoter region is not
sufficient for expression of the TRAP gene in vivo and in vitro
and by showing that the exon 1B transcript is the predominant
TRAP mRNA in transgenic mice with the 2.2-kb TRAP pro-
moter. As the great majority of currently studied transcription
factors that influence TRAP gene expression bind within the
1.6-kb C region of the TRAP promoter, our findings strongly
FIG. 6. Transgene expression in osteoclastogenic culture from BC and C mice. Levels of mRNA for total endogenous TRAP (A) and total
NGFRCDy (B) is shown in osteoclasts and macrophages of BC and C mice. Endogenous TRAP B transcript (C), endogenous TRAP C transcript (D),
NGFRCDy B transcript (E), and NGFRCDy C transcript (F) is shown in osteoclasts of BC mice. Expression ratios are relative
to HPRT.
FIG. 7.Detection of NGFRCDy fusion protein in vitro. A, bone marrow from control (C3H/HeJ) and BC transgenic mouse bone marrow was
grown in vitro for 6 days with RANKL and MCSF. Replicate wells of osteoclasts from C3H/HeJ (A, B) and BC (C, D) mice were stained for NGFR
(A, C), TRAP (B), or NGFR and TRAP (D). Osteoclasts (garnet-stainedmultinucleated cells) formed in all wells. However, NGFR (brown) is present
only in osteoclasts formed from transgenic bone marrow (400). Double-positive staining for TRAP (arrows) and NGFR can be seen in osteoclasts
from BC mice (D). E, activity of CDy was assessed in osteoclastogenic cultures. Bone marrow from C3H/HeJ (--), or BC (-●-) mice was cultured
in the presence of RANKL (20 ng/ml) and MCSF (30 ng/ml) with increasing doses of 5FC. *, p 0.01, n  4.
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suggested that transcription factor binding sites upstream of
the C region will also have profound effects on regulation of the
TRAP gene.
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